TNF and rheumatoid arthritis: Regarding the effects of the type of TNF-α inhibitor employed in our study (i.e., etanercept or adalimumab) on the levels of bone turnover markers (PINP, CTX-I) and osteoclast regulators (sRANKL, OPG) in female RA patients, our results have not demonstrated any superiority of ETA therapy in terms of preventing bone damage when compared to ADA.